Table 1 Baseline features of the extension BODI cohort (n=189)
Demographics | |
Male gender, n (%) | 92 (48.7) |
Age at enrolment, mean (SD) years | 46.2 (12.1) |
Age at the disease onset, mean (SD) years | 32.6 (11.3) |
Age at diagnosis, mean (SD) years | 35.5 (11.1) |
Disease duration, mean (SD) years | 10.8 (8.3) |
Cumulative clinical manifestations | |
Oral aphtosis, n (%) | 186 (98.4) |
Genital aphtosis, n (%) | 137 (72.5) |
Skin lesions, n (%) | 137 (72.5) |
Ocular manifestations, n (%) | 108 (57.1) |
Neurologic lesions, n (%) | 37 (21.8) |
Vascular lesions, n (%) | 41 (21.7) |
Pathergy test, n (%) | 25 (13.2) |
Arthritis, n (%) | 107 (57.5) |
Gastrointestinal manifestation, n (%) | 27 (14.7) |
Active clinical manifestations | |
Oral aphtosis, n (%) | 63 (33.3) |
Genital aphtosis, n (%) | 12 (6.3) |
Skin lesions, n (%) | 20 (10.6) |
Ocular manifestations, n (%) | 12 (6.4) |
Neurologic lesions, n (%) | 5 (2.7) |
Vascular lesions, n (%) | 3 (1.6) |
Arthritis, n (%) | 17 (9.3) |
Gastrointestinal manifestation, n (%) | 9 (5.0) |
Ongoing treatment | |
Glucocorticoid ongoing, n (%) | 93 (49.2) |
Glucocorticoid duration, mean (SD) months | 54.9 (66.6) |
Conventional Immunosuppressantsa, n (%) | 81 (42.9) |
TNF inhibitors, n (%) | 44 (23.3) |
Disease activity | |
BDCAF, mean (SD) score | 2.7 (2.8) |
PGA, mean (SD) cm | 2.0 (2.1) |
PtGA, mean (SD) cm | 2.8 (2.6) |
Damage | |
BODI, mean (SD) score | 1.6 (2.0) |
BODI ≥1, n (%) | 114 (60.3) |